Clinical Trials Logo

Gliosarcoma clinical trials

View clinical trials related to Gliosarcoma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT00823797 Active, not recruiting - Adult Glioblastoma Clinical Trials

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Start date: October 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well bendamustine hydrochloride works in treating patients with anaplastic glioma or glioblastoma that has come back (recurrent) or growing, spreading or getting worse (progressive). Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

NCT ID: NCT00268385 Active, not recruiting - Adult Glioblastoma Clinical Trials

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Start date: December 16, 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.

NCT ID: NCT00114309 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

Start date: November 2004
Phase: Phase 2
Study type: Interventional

This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.

NCT ID: NCT00102648 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide

Start date: December 21, 2004
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not respond to previous treatment with temozolomide. Lonafarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lonafarnib together with temozolomide may kill more tumor cells.

NCT ID: NCT00045110 Active, not recruiting - Adult Glioblastoma Clinical Trials

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Start date: August 2002
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.